Literature DB >> 33932686

The inhibitory NK receptor Ly49Q protects plasmacytoid dendritic cells from pyroptotic cell death.

Shigemi Sasawatari1, Hitomi Karyu1, Dat Nguyen Tien1, Kaori Furuyama-Tanaka1, Noriko Toyama-Sorimachi2.   

Abstract

Ly49Q is an ITIM-bearing MHC class I receptor that is highly expressed in plasmacytoid dendritic cells (pDCs). Ly49Q is required for the TLR9-mediated IFN-I production in pDCs, although the mechanism is not fully understood. We here demonstrate that Ly49Q protects pDCs from pyroptotic cell death induced by CpG oligodeoxynucleotides (CpG). In the Ly49Q-deficient (Klra17-/-) mouse spleen, the number of ssDNA-positive pDCs increased significantly after CpG treatment, strongly suggesting that Klra17-/- pDCs were susceptible to CpG-induced cell death. In Klra17-/- bone-marrow-derived dendritic cells (BMDCs), CpG-induced cell death was accompanied by increased cathepsin B leakage from the vesicular compartments into the cytoplasm. Concurrently, IL-1β secretion increased in the CpG-treated Klra17-/- BMDCs, strongly suggesting that the CpG-induced cell death in these cells is pyroptotic in nature. Consistent with these observations, inhibiting cathepsin B or caspase 1 in CpG-stimulated Klra17-/- BMDCs reversed the increase in cell death. Pyroptotic cell death and IL-1β secretion were also observed in BMDCs derived from transgenic mice expressing an ITIM-less Ly49Q (Ly49Q-YF Tg). CpG also increased the IL-1β production and cell death in B2m-/- BMDCs. These results suggest that Ly49Q and MHC class I play important roles for protecting pyroptosis-like cell death of DCs by influencing lysosome state.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell surface molecule; MHC class I; NK receptor; Plasmacytoid dendritic cells; Pyroptosis; Rodent; Toll-like receptor

Year:  2021        PMID: 33932686     DOI: 10.1016/j.molimm.2021.03.023

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  1 in total

Review 1.  Licensing Natural Killers for Antiviral Immunity.

Authors:  John M Cronk; Eleni Fafoutis; Michael G Brown
Journal:  Pathogens       Date:  2021-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.